Expression and prognostic value of FAS receptor/FAS ligand and TrailR1/TrailR2 in acute myeloid leukemia

References

• Krammer PH, Dhein J, Walczak JH, Behrmann I, Mariani S, Matiba B, et al.. The role of APO-1-mediated apoptosisin the immune system. Immunol Rev 1994;142:175–91.
   PubMed Web of Science ®Google Scholar
• Josien R, Müschen M, Gilbert E, Douillard P, Heslan JM, Soulillou JP, Cuturi MC. Fas ligand, tumor necrosis factor-alpha expression,and apoptosis during allograft rejection and tolerance. Transplantation 1998;66(7):887–93.
   PubMed Web of Science ®Google Scholar
• Pan G, O’Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, et al.. The receptor for the cytotoxic ligandTRAIL. Science 1997;276:111–3.
   PubMed Web of Science ®Google Scholar
• Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin DK. Control of TRAIL-induced apoptosis by a familyof signaling and decoy receptors. Science 1997;277(5327):818–21.
   PubMed Web of Science ®Google Scholar
• Walczak H, Degli-Eposti HA, Johnson RS, Smolak PJ, Waugh YJ, Boiani N, et al.. TRAIL-R2: a novel apoptosis-mediatingreceptor for TRAIL. EMBO J 1997;16:5386–97.
   PubMed Web of Science ®Google Scholar
• Screaton GR, Mongkolsapaya N, Xu JX, Cowper AE, McMichael AJ, Bell JI. TRICK 2, a new alternatively spliced receptorthat transduces the cytotoxic signal from TRAIL. CurrBiol 1997;7:693–6.
   PubMed Web of Science ®Google Scholar
• Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of the TNFRfamily, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaBpathway. Immunity 1997;7(6):821–30.
   PubMed Web of Science ®Google Scholar
• Schneider P, Tschopp J. Modulation of death receptor signalling. SympSoc Exp Biol 2000;52:31–42.
   PubMedGoogle Scholar
• MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GE, Alnemri ES. Identification and molecular cloning of twonovel receptors for the cytotoxic ligand TRAIL. JBiol Chem 1997;272:25417–20.
   PubMed Web of Science ®Google Scholar
• Degli-Eposti MA, Dougall MC, Smolka PJ, Waugh YJ, Smith CA, Goodwin RG. The novel receptor Trail-R4 induces NF-B andprotects against TRAIL-mediated apoptosis, yet retains an incomplete deathdomain. Immunity 1997;7:813–20.
   PubMed Web of Science ®Google Scholar
• Marsters SA, Pitti RM, Donahue CJ, Ruppert S, Bauer KD, Ashkenazi A. Activation of apoptosis by Apo-2 ligand isindependent of FADD but blocked by CrmA. Curr Biol 1996;6:750–2.
   PubMed Web of Science ®Google Scholar
• Delia D, Accomero P, Redrizzani M, Gerosa F, Kurrle R, Colombo MP. Differential susceptibility to HIV-GP120-sensilizedapoptosis in CD4+-T-cell clones with different T helper phenotypes: roleof CD95/CD95L interactions. Blood 1997;89(2):558–69.
   PubMed Web of Science ®Google Scholar
• Traver D, Akashi K, Weismann IL, Lagasse E. Mice defective in two apoptosis pathways inthe myeloid lineage develop acute myeloblastic leukaemia. Immunity 1998;9(1):47–57.
   PubMed Web of Science ®Google Scholar
• Gores G, Chen XJ, Paya CV, la Russo NF. Cryptosporidium parvum induced apoptosis inbiliary epithelia by a Fas-Fas-ligand-dependent mechanism. AmJ Physiol 1999;277(3Pt1):G599–608.
   PubMedGoogle Scholar
• Rieux-Laucat F, Fischer A, Deist FL. Cell-death signalling and human disease. CurrOpin Immunol 2003;15(3):325–31.
   PubMed Web of Science ®Google Scholar
• Buzyn A, Petit F, Ostankovitch M, Figueiredo S, Varet B, Guillet JG, et al.. Mambran-Bound Fas (Apo-1/CD95) Ligandon leukemic cells: a mechanism of tumor immune escape in leukemia patients. Blood 1999;94(9):3135–40.
   PubMed Web of Science ®Google Scholar
• Bennett JM, Catovsky D, Daniel MT. Proposals for the classification of the acuteleukemias. French-American-British (FAB) co-operative Group. BrJ Haematol 1976;33:451–8.
   PubMed Web of Science ®Google Scholar
• Mrozek K, Heinonen K, de la Chapette A, Bloomfield CD. Clinical significance of cytogenetics in acutemyeloid leukemia. Semin Oncol 1997;24:17–31.
   PubMed Web of Science ®Google Scholar
• Schoch C, Schnittger S, Klaus M, Kern W, Hiddemann W, Haferlach T. AML with 11q23/MLL abnormalities as definedby the WHO classification: incidence, partner chromosomes, FAB subtype, agedistribution, and prognostic impact in an unselected series of 1897 cytogeneticallyanalyzed AML cases. Blood 2003;102:2395–420.
   PubMed Web of Science ®Google Scholar
• Rothe G, Schmitz G. (working group on flow cytometry and imageanalyses). Consensus protocol for the flow cytometric immunophenotying ofhematopoietic malignancies. Leukemia 1996;10:877–95.
   PubMed Web of Science ®Google Scholar
• Graf M, Hecht K, Reif S, Pelka-Fleischer R, Pfister K, Schmetzer H. Expression and prognostic value of hemopoieticcytokine receptors in acute myeloid leukemia (AML): implications for futuretherapeutical strategies. Eur J Haematol 2004;72(2):89–106.
   PubMed Web of Science ®Google Scholar
• Iijima N, Miyamura K, Itou T, Tanimoto M, Sobue R, Saito H. Functional expression of Fas (CD95) in acutemyeloid leukemia cells in the context of CD34 and CD38 expression: possiblecorrelation with sensitivity of chemotherapy. Blood 1997;90(12):4901–9.
   PubMed Web of Science ®Google Scholar
• Almodovar R, Zarco P, Quiros FJ, Mazzucchelli R. Infliximab treatment efficacy in lymphoedemaassociated with ankylosing spondylitis. Rheumatol 2004;43(11):1456.
   PubMed Web of Science ®Google Scholar
• Shipmann CM, Croucher PI. Osteoprotegerin is a soluble decoy receptorfor tumor necrosis factor-related apoptosis-inducing ligand/Apo 2 ligand andcan function as a paracrine survival factor for human myeloma cells. CancerRes 2003;63(5):912–6.
   Web of Science ®Google Scholar
• Riccioni R, Pasquini L, Mariani G, Saulle E, Rossini A, Diverio D, et al.. Trail decoy receptors mediate resistanceto acute myeloid leukemia cells to TRAIL. Haematologica 2005;90(5):612–24.
   PubMed Web of Science ®Google Scholar
• Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, et al.. Inhibitors of histone deacetylasesinduce tumor-selective apoptosis through activation of the death receptorpathway. Nat Med 2005;11(1):71–6.
   PubMed Web of Science ®Google Scholar
• Xue C, Lan-Lan W, Bei C, Jie C, Wei-Hua F. Abnormal Fas/FasL and caspase-3-mediated apoptoticsignaling pathways of T lymphcyte subsets in patients with systemic lupuserythematosus. Cell Immunol 2006;239(2):121–8.
   PubMedGoogle Scholar
• Lickliter JD, Kratzke RA, Nguyen PL, Niehans GA, Miller JS. Fas ligand is highly expressed in acute leukemiaand during the transformation of chronic myeloid leukemia to blast crisis. ExpHematol 1999;27(10):1519–27.
   PubMed Web of Science ®Google Scholar
• Lee IJ, Chung IJ, Park MR, Ryang DW, Park CS, Kim HJ. Increased angiogenesis and Fas-ligand expressionare independent processes in acute myeloid leukaemia, Leuk Res 2001;25(12):1067–73.
   Google Scholar
• Min YJ, Lee HJ, Choi SJ, Chi HS, Lee JS, Kim WK, et al.. Prognostic significance of Fas(Cd95)and TRAIL receptors (DR4/DR5) expression in acute myelogenous leukaemia. LeukRes 2004;28(4):39–65.
   Web of Science ®Google Scholar
• Lewis NR, Pallis M, Russel NH. Fas receptor-Fas ligand system is independentof both CD34 status and chemosensitivity in acute myeloid leukemis. ExpHematol 2000;28(5):535–42.
   PubMedGoogle Scholar
• Iwai K, Miyawaki T, Takizawa T, Konno A, Ohta K, Yachie A, et al.. Differential expression of bcl-2 andsusceptibility to anti-Fas-mediated cell death in periphl blood lymphocytes,monocytes and neutrophils. Blood 1994;84(4):1201–8.
   PubMed Web of Science ®Google Scholar
• Zhao S, Wang HX, Mao H, Xiao J, Zou P. Expression and its significance of TRAIL andits receptors in cells of patients with acute myeloid leukaemia. ZhongguoShi Yan Xue Za Zhi 2005;13(1):65–9.
   PubMedGoogle Scholar
• Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Ofao A, et al.. Proposal for the immunological classificationof acute leukemias. European Group for the Immunological Characterizationof Leukemias (EGIL). Leukemia 1995;9(10):1783–6.
   PubMed Web of Science ®Google Scholar
• Findley HW, Zhou M. The clinical significance of Fas expressionin leukemia; questions and controversies. Leukemia 1999;13(2):147–9.
   PubMed Web of Science ®Google Scholar
• Kelley S, Ashkenazi A. Targeting death receptors in cancer with Apo-2L/TRAIL. CurrOpin Pharmacol 2004;4(4):333–9.
   Google Scholar
• Johnston JB, Karborl AF, Strutinsky J, Hu X, Paul JT, Kropp DM. Role of the TRAIL/APO2-L death receptors inchlorambucil-and fludarabine-induced apoptosis in chronic lymphcytic leukemia. Oncogene 2003;22(51):8356–69.
   PubMedGoogle Scholar
• Insinga A, Minucci S, Palicci PG. Mechanisms of selective anticancer actionof histone deacetylase inhibitors. Cell Cycle 2005;4:741–3</pages>.
   PubMed Web of Science ®Google Scholar
• Selleri C, Maciejewski JP, Pane F, Luciano L, Raiola AM, Mostarda I. Fas-mediated modulation of Bcr/Abl in chronicmyelogenous leukemia results in differential effects on apoptosis. Blood 1998;92(3):981–9.
   PubMed Web of Science ®Google Scholar
• Kasibhatla S, Genstier L, Green DR. Regulation of fas-ligand expression duringactivation-induced cell death in T lymphocytes via nuclear factor kappa B. JBiol Chem 1999;274(2):987–92.
   PubMed Web of Science ®Google Scholar
• Morales J, Magana MJ, Ruiz-Ruiz C. Regulation of the resitance to Trail-inducedapoptosis in human primary T lymphocytes: role of NF-κB inhibition. MolImmunol 2007;44(10):2587–97.
   Google Scholar
• Dorothee G, Vergnon I, Menez J, Echchakir H, Grunenwald D, Kubin M. Tumor-infiltrating CD4+ Tlymphocytes express APO2 ligand (APO2L)/TRAIL upon specific stimulation withantologous lung carcinoma cells: role of IFN-alpha on APO2L/TRAIL expressionand-mediated cytotoxity. J Immunol 2002;169(2):809–17.
   PubMedGoogle Scholar
• Hasegawa H, Yamada Y, Harasawa H, Tsuji T, Murata K, Sugahara K. Restricted expression of tumor necrosis factor-relatedapoptosis-inducing ligand receptor 4 in human peripheral blood lymphocytes. CellImmunol 2004;231(1–2):1–7.
   PubMed Web of Science ®Google Scholar